Finally, although some controversies still remain and warrant further studies, accumulating evidence showed that SSTR2-related/targeted treatments (e.g., somatostatin analogs and SSTR2-targeted peptide receptor radionuclide therapy (PRRT)) are promising and safe therapeutic options for unresectable or refractory meningiomas [23,25,86,87]. Here, SST is linked to meningioma.